Driving digital in biopharma: Podcast

Episode #12

Host Tom Lehmann talks with Lars Fogh Iversen, Senior Vice Present for Digital Science and Innovation at Novo Nordisk. They discuss the journey to accelerate research and early development through laboratory automation, data management, AI and digital research.

Episode #10

In this episode, Savyon Amit shares how AstraZeneca came to an aligned understanding of Digital Health, with specific and distinct digital health objectives while also being unified and complementary across the R&D and commercial functions. Savyon and Tom also discuss the importance of articulating the value of digital from an organizational standpoint as well as value to the broader healthcare ecosystem.

Episode #8

In this episode Venkat Sethuraman, SVP Global Biometrics and Data Science, Bristol Myers Squibb talks with Tom Lehmann about the critical role of data, design and digital in the future vision for R&D.

Venkat discusses what BMS calls “3D for R&D” and describes how data, design and digital is creating value with patients and stakeholders. 3D for R&D begins with the opportunity for innovation created by the availability and accessibility of data in advancing drug development. Design involves how to use data to better design efficient studies and accelerate our clinical programs, and the third element, digital, is powered by insights and feedback from patients and investigators.

Our Technology Vision 2021 for Life Sciences revealed that leaders don’t sit back and wait for the “new normal”. They build it themselves. Big changes today require bold, innovative leadership that prioritizes technology.

Each of the five trends (Stack Strategically; Mirrored World; I, Technologist; Anywhere Everywhere and From Me to We) are rooted in the disruptions and demands caused by the COVID-19 pandemic that set a high bar for life sciences companies—with many meeting or exceeding expectations.

In this series of short episodes, I’ll talk with five Accenture Life Sciences leaders who helped shape our industry perspective of the Tech Vision to inspire life sciences companies to embrace a new mindset to shape a better future. Their thinking is backed by a survey of 100 biopharma business and IT executives across seven countries that helped identify the key issues and priorities for technology adoption and investment.

Stack Strategically – View Transcript

Mirrored World – View Transcript

I, Technologist – View Transcript

Anywhere, Everywhere – View Transcript

From Me to We – View Transcript

Episode #6

In this episode Tom connects with John Kelleher, head of digital quality for Pfizer global supply. John shares a unique perspective on how this organization is connecting learnings and impacts of a digital transformation pilot on the QA side, to the newer, current and more holistic transformation initiatives on the QC side.

John discusses Pfizer’s lab of the future strategy and its focus on improving process and performance through the lens of the talented people who work there. John's experience bridging technology and business process comes to the forefront of this discussion.

Episode #4

In this episode our podcast host Tom Lehmann talks health and patient care innovation with Tina Ripperger and Jennifer Spada. This episode focuses on the healthcare disruption we all faced in 2020-21 and the role digital is playing to connect and engage with patients.

They discuss the historic 2020 reset that forced the need for patients to adopt new ways of managing their health and findings from a recent patient services survey Accenture led that gained insights on new trends in care from 12,000 patients around the world.

The three take on how the health experiences have been forever revolutionized and discuss how some of the most successful companies are leading the way to lasting changes that positively impact patient health.

Episode #2

In this episode Accenture’s Tom Lehmann talks with Kailash Swarna, Ph.D, MBA, Novo Nordisk. They discuss Kailash’s role in applying a digital transformation mindset to increase patient impact and improve the lives of people with diabetes and metabolic diseases.

The discussion candidly takes on strategy and stakeholders, the pace of technology and science, the dimensions of patient centricity, making value tangible, and future vision.